Abstract
Material and Methods
Within the group of 47 patients treated with peptide receptor radionuclide therapy
(PRRT), four patients were chosen: three with inoperable tumors without liver metastases
and one with two lesions in the pancreas and metastases.
Results
In all patients, after PRRT, the changes in the sum of the longest diameters of tumors
were between −1% and −21%, resulting in stable disease reported [strict Response Evaluation
Criteria in Solid Tumors (RECIST)]. But the measurements of tumor volume and attenuation
in computed tomography and the tumor to nontumor ratio in somatostatin receptor scintigraphy
resulted in different response assessments.
Conclusions
The RECIST standard may be not sufficient to properly assess the therapy response
in patients with neuroendocrine tumors.
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Clinical ImagingAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Gastroenteropancreatic neuroendocrine tumors.Lancet Oncol. 2008; 9 ([PMID 18780869]): 61-72
- Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system.Ann Oncol. 2004; 15 ([PMID 15151956]): 966-973
- Neoadjuvant peptide receptor radionuclide therapy for an inoperable neuroendocrine pancreatic tumor.World J Gastroenterol. 2009; 15 ([PMID 19998512]): 5867-5870
- Successful neoadjuvant therapy with trastuzumab, paclitaxel and epirubicin for an elderly patient with inflammatory breast cancer.Anticancer Res. 2010; 2 ([PMID 20332474]): 581-585
- Individualized peptide-related-radionuclide-therapy concept using different radiolabelled somatostatin analogs in advanced cancer patients.Q J Nucl Med Mol Imaging. 2010; 54 ([PMID 20168291]): 92-99
- The diagnosis and medical management of advanced neuroendocrine tumors.Endocr Rev. 2004; 25 ([PMID 15180952]): 458-511
- New guidelines to evaluate the response to treatment in solid tumors.J Natl Cancer Inst. 2000; 92 ([PMID 10655437]): 205-216
- New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).Eur J Cancer. 2009; 45 ([PMID 19097774]): 228-247
- Staged surgery with neoadjuvant 90Y-DOTATOC therapy for down-sizing synchronous bilobular hepatic metastases from a neuroendocrine pancreatic tumor.Langenbecks Arch Surg. 2010; 395 ([PMID 19506898]): 185-192
- Imaging of gastroenteropancreatic neuroendocrine tumors.World J Clin Oncol. 2011; 2 ([PMID 21603312]): 28-43
- Guidelines for the diagnosis and treatment of neuroendocrine gastrointestinal tumours. A consensus statement on behalf of the European Neuroendocrine Tumour Society (ENETS).Neuroendocrinology. 2004; 80 ([PMID 15838182]): 394-424
- Peptide receptor radionuclide therapy as a potential tool for neoadjuvant therapy in patients with inoperable neuroendocrine tumours (NETs).Eur J Nucl Med Mol Imaging. 2011; 38 ([PMID: 21559978]): 1669-1674
- Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria.J Clin Oncol. 2007; 25 ([PMID 17470865]): 1753-1759
- Design and endpoints of clinical trials in hepatocellular carcinoma.J Natl Cancer Inst. 2008; 100 ([PMID 18477802]): 698-710
Article info
Publication history
Published online: December 16, 2011
Accepted:
November 3,
2011
Received:
September 1,
2011
Footnotes
☆No potential conflicts of interest were disclosed.
Identification
Copyright
© 2012 Elsevier Inc. Published by Elsevier Inc. All rights reserved.
